The capital invested in the promise of future cures for Alzheimer's and Parkinson's disease relieved the CEO of duties accused of plagiarism decades past. The investigation that followed confirmed the ethical lapse and the CEO resigned to the polite applause of shareholders hanging on for the ride.
37 million shares outstanding. Perceptive Advisors at 9%. Usual institutional suspects over 50%. Public at 27%.
mc 472
No comments:
Post a Comment